Special Issue "Targeted Therapy for Small Cell Lung Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (28 September 2019) | Viewed by 17127
Interests: ccRCC; NGS; TSGs; LUAD driver mutations; microRNAs; intratumor heterogeneity
Special Issues, Collections and Topics in MDPI journals
The therapy of non-small cell lung cancer (NSCLC) has seen major advances in therapeutic modalities involving the targeting of a range of driver kinases and the activation of the immune system by checkpoint inhibitors. In contrast, small cell lung cancer (SCLC), which constitutes approximately 15% of lung cancers, poses a much tougher problem, and its treatment has lacked significant advances for the past decades, with the possible exception of the recent successes of immunotherapy. However, the response rates to immunotherapy are rather low and linked to a modest prolongation of survival, and, therefore, there is much room for improvement in the targeted therapy of SCLC. The genomic characterization of SCLC has revealed the universal impairment of p53 and pRb tumor suppressor proteins and the presence of multiple interchangeable drivers which are difficult to target. A host of targeted therapies aimed at reversing resistance to apoptosis and inhibiting developmental signaling pathways and growth factor receptors failed to show clinical progress. Investigations on inhibitors of DNA repair, global modifiers of gene transcription, or cytotoxic drug conjugates directed to constituents of growth stimulatory circuits are ongoing. In the past, SCLC was preferentially studied by two-dimensional tumor models or poorly representative xenografts. The three-dimensional nature and organization of SCLC tumors has been largely neglected, although vigorously proliferating tumors may outgrow vessel supply and may show avascular tumor areas comprising hypoxic regions with resulting chemo- and radioresistance. Likewise, the importance of the growth of circulating tumor cells (CTC) as three-dimensional aggregates in metastasis and drug resistance has not been considered in the treatment of SCLC so far. Therefore, for this Special Issue on targeted therapy for SCLC, all kinds of new concepts, alternative druggable targets and, especially, means to reverse drug resistance at the multicellular level are invited.
Dr. Klaas Kok
Dr. Birgitta I Hiddinga
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- small cell lung cancer
- targeted therapy
- cell signaling inhibitors
- kinase inhibitors
- transcription modifiers
- drug conjugates